Get startedLog in
    Picture of PhaseBio Pharmaceuticals logo

    PHASQ — PhaseBio Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro Cap
    All News

    Brief: PhaseBio Pharmaceuticals Reports QTRLY Loss Per Share Of $0.98

    Picture of PhaseBio Pharmaceuticals logoPhaseBio Pharmaceuticals
    11/08/2020 21:14
    Aug 11 (Reuters) - PhaseBio Pharmaceuticals Inc  PHAS.O :
    * PHASEBIO REPORTS RECENT BUSINESS HIGHLIGHTS AND
SECOND-QUARTER
2020 FINANCIAL RESULTS
    * PHASEBIO PHARMACEUTICALS INC- QTRLY LOSS PER SHARE $0.98
    * PHASEBIO PHARMACEUTICALS - RECEIVED FDA AUTHORIZATION TO
PROCEED
WITH “VANGARD” TRIAL FOR EFFICACY & SAFETY OF PB1046 IN
HOSPITALIZED COVID-19 PATIENTS

Source text for Eikon:  ID:nBw5ysZwNa 
Further company coverage:  PHAS.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on PhaseBio Pharmaceuticals

    See all news